Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: jlib who wrote (1265)	8/30/1998 2:34:00 PM
From: WeirdPro Randy	Read Replies (1) \| Respond to of 1359

<<Wurtman's protestation that "They should never have been prescribed together" is a bit disingenuous. Does anyone remember IPIC releasing any memos to physicians discouraging that use?>> When we discuss IPIC, we are only concerned about Redux, which was developed as an alternative to "phen-fen" (Pondimin plus phentermine), and for which the majority usage (96% of Redux patients) were never prescribed the combination. The well known combining of Pondimin and phentermine is a large legal contention already in which plaintiff's lawyers argue the company should have done more to stop or discourage this........but this is AHP's problem, not IPIC's. IPIC had no part in these drugs. With regards to the question of evaluating the original patients, I don't know .....however the studies to come should give some good information regarding both Redux and phen-fen.